PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Inflammatory bowel disease (Sulfasalazine - Inflammatory bowel disease)

Records returned : 40 (on 24 Nov 2024 at 03:17:35). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.05.01
10.01.03
Sulfasalazine
Inflammatory bowel disease
Amber
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Enteric coated tablets are significantly more expensive. Reserve for patients unable to tolerate plain tablets.
01.05.01
10.01.03
Inflammatory bowel disease
Amber
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.05.01
10.01.03
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Tablets can be dispersed for immediate administration.
01.05.02
11.04.01
Inflammatory bowel disease
Green
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Paediatrics only at SASH. Paediatrics and oncology at ASPH
01.05.02
11.04.01
Inflammatory bowel disease
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Paediatric doses and NG/NJ tube only
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
Green
Formulations :
  • Foam enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Steroid safety considerations
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary
01.05.01
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Octasa, Salofalk, Pentasa
01.05.01
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Mezevant XL - Reserve for patients with a high pill burden.
01.05.01
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Granules (slow release)
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.
01.05.01
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Enema
  • Foam enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Pentasa / Salofalk enema
01.05.03
08.02.01
Azathioprine
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
08.02.01
Mercaptopurine
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
01.05.03
10.01.03
13.05.03
Methotrexate
Inflammatory bowel disease
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
DO NOT prescribe or supply 10mg tablets. WEEKLY dose frequency. Advise patients to carry the patient alert card / book
01.05.03
10.01.04
Allopurinol
Inflammatory bowel disease
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Off-label use in combination with azathioprine and mercaptopurine
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Inflammatory bowel disease
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Ulcerative colitis only. Prescribe by brand
Ulcerative colitis only
01.05.03
10.01.03
11.08.03
13.05.03
Adalimumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For UC & CD. Adults only. Prescribe by brand.
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For UC & CD. Prescribe by brand
01.05.03
10.01.03
13.05.03
Golimumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative Colitis in Adults only. Prescribe by brand.
Ustekinumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Adults only.
01.05.03
10.01.03
13.05.03
Upadacitinib
Inflammatory bowel disease
Red
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative colitis in Adults only.
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For UC & CD. Adults only
Ozanimod
Inflammatory bowel disease
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative Colitis - adults only.
Etrasimod
Inflammatory bowel disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative colitis only
NICE guidance applies to Ulcerative Colitis patients only
01.05.03
10.01.03
Filgotinib
Inflammatory bowel disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative colitis - adults only
01.05.03
10.01.03
Tofacitinib
Inflammatory bowel disease
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative colitis - adults only
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Inflammatory bowel disease
Red
Formulations :
  • Capsules
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Ulcerative colitis only. Prescribe by brand
Mirikizumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative Colitis - adults only.
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
Red
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Steroid safety considerations
3mg MR capsules - gastroenterology team only
01.05.03
Vedolizumab
Inflammatory bowel disease
Red
Formulations :
  • Infusion
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Not 1st line. Only in patients where steroids and/or TNF inhibitor not effective / appropriate
Guidelines
Inflammatory bowel disease
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Inflammatory bowel disease
N/A
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.05.02
05.03.06
06.03.02
Budesonide
Inflammatory bowel disease
N/A
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
Important
Steroid safety considerations
Not assessed for formulary status. Applications for formulary entry via APC.
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Enteric coated tablets - non-formulary
01.05.01
Mesalazine
Inflammatory bowel disease
Non Formulary
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.
01.05.01
Olsalazine sodium
Inflammatory bowel disease
Non Formulary
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Licensed in mild ulcerative colitis
01.05.01
Balsalazide sodium
Inflammatory bowel disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Darvadstrocel
Inflammatory bowel disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
For Crohn's disease only
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Foam enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Budesonide rectal foam is preferred. Steroid safety considerations
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More